Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of therapies aimed at treating rare and difficult-to-manage medical conditions. The company’s current commercial portfolio includes three approved products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

As per Kalkine’s Diversified Opportunities Report published on ‘CPRX’ on Jul 24, 2025, Kalkine provided an ‘Buy’ stance on the stock at USD 21.57 based on fundamental analysis and the stock price has now moved up by ~ 14.46% since then.

Noted below are the details of support and resistance levels provided in our previous report:

Rationale:

Despite reporting Q4FY25 earnings and revenue above consensus expectations, Catalyst Pharmaceuticals faces emerging headwinds that could temper the sustainability of its recent performance. Revenue concentration remains high in Firdapse, while Fycompa is already experiencing a sharp decline following patent expirations and the entry of generic competition, with further erosion expected as additional generics enter the market. Although Agamree is contributing incremental growth following its recent launch, the product remains in the early stages of commercialization and may require sustained marketing investment. At the same time, rising SG&A expenses and potential increases in R&D spending tied to future acquisitions could pressure margins.

Valuation (Using Price/Earnings Multiple)

Share Price Chart  

Conclusion

Following a significant share price outperformance relative to the broader industry, alongside rising generic competition for Fycompa, revenue concentration in Firdapse, and ongoing patent litigation uncertainty, a "Sell" recommendation on Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) has been given at the closing market price of USD 24.69 as on 04 March 2026.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 04 March 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.